规格 | 目录价格 | 上海 | 安徽 | 武汉 | 成都 | 北方 | 深圳 | 会员价格 | 数量 |
---|---|---|---|---|---|---|---|---|---|
0mg | ¥ ñćĩƯƯ | -- | > 10 | -- | -- | -- | -- | ¥ ñćĩƯƯ | - + |
100mg | ¥ łǴćĩƯƯ | -- | > 10 | -- | -- | ¥ łǴćĩƯƯ | - + | ||
0mg | ¥ łƂĴĩƯƯ | -- | > 10 | 1 | -- | ¥ łƂĴĩƯƯ | - + | ||
1g | ¥ ĞśƯĩƯƯ | -- | > 10 | -- | 1 | -- | ¥ ĞśƯĩƯƯ | - + | |
g | ¥ łĴłƂĩƯƯ | -- | 7 | -- | -- | -- | -- | ¥ łĴłƂĩƯƯ | - + |
10g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
100g | 请询价 | -- | -- | -- | -- | -- | -- | -- | - + |
10.04
[1]. Bollard J, et al. Palbociclib (PD-0331), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut. 017 Jul;66(7):186-16.
[]. Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0331 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 004 Nov;3(11):147-38.
[3]. Goel S, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 017 Aug 4;48(7668):471-47.
[4]. Richard S Finn, et al. PD 0331, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 00;11():R77.
P60-P64-P70-P73-P80-P330-P01
GHS08,GHS0